Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy. Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature.
Beldner
Matthew
M
Department of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA. beldner@musc.edu
Jacobson
Michael
M
Burges
Gene E
GE
Dewaay
Deborah
D
Maize
John C
JC
Chaudhary
Uzair B
UB
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor